InflaRx N.V. (Nasdaq: IFRX), a biotechnology company
pioneering anti-inflammatory therapeutics targeting the complement
system, announced today financial results for the three and nine
months ended September 30, 2023, and provided an operating update.
“In recent months, we have made exciting
progress with both vilobelimab and our small molecule C5aR
inhibitor INF904. With the commercial launch of Gohibic
(vilobelimab) in the United States now underway, we are also
advancing vilobelimab in pyoderma gangrenosum, recently initiating
a Phase III trial in this debilitating skin disease,” said Prof.
Niels C. Riedemann, Chief Executive Officer and Co-founder of
InflaRx.
He continued: “With INF904, we set out to
develop an orally bioavailable inhibitor of C5a signaling with
best-in-class potential, and the initial data from our Phase I
trial strongly support this. We look forward to seeing additional
data from this ongoing study with this promising treatment
candidate. Ultimately, we are planning to develop INF904 in a
chronic inflammatory condition and dedicate more resources towards
this exciting new development going forward.”
Recent Highlights and Business
Update
INF904 – Positive Topline Results from
Single Ascending Dose (SAD) Part of Phase I Trial Support
Best-in-Class Potential as Orally Administered C5aR
Inhibitor InflaRx recently announced positive topline
results from the SAD part of a randomized, double-blind,
placebo-controlled Phase I trial in healthy volunteers to assess
the safety, tolerability and pharmacokinetic / pharmacodynamic
(PK/PD) properties of InflaRx’s low molecular weight C5aR inhibitor
INF904.
The results showed that INF904 was well
tolerated and resulted in no safety signals of concern in single
doses ranging from 3 mg to 240 mg. Analysis of INF904 in subject
plasma samples revealed a favorable PK profile that, at the 30 mg
dose and above, surpassed the values for systemic exposure
(AUClast) and maximum concentration (Cmax) of published Phase I
data from the only marketed comparator. Further, ex vivo assays
showed that INF904 achieved the set goal for effective C5aR control
at disease relevant C5a levels.
The multiple ascending dose (MAD) part of the
Phase 1 trial is ongoing, and the Company expects to present
results from the approximately 24 healthy volunteers enrolled in
this part of the study at the beginning of 2024. InflaRx is
currently preparing to initiate additional required pre-clinical
studies, including chronic toxicology studies, for the future
clinical development of INF904 in chronic inflammatory diseases. In
parallel, the Company is evaluating selected potential indications
for future development.
Development of Vilobelimab in Pyoderma
Gangrenosum (PG):InflaRx is well underway in a pivotal
Phase III study with vilobelimab for the treatment of ulcerative
PG. As of today, InflaRx has initiated the first six clinical sites
in the United States and is actively screening patients. The
Company foresees being able to start treating the first patient
very soon. The multi-national, randomized, double-blind,
placebo-controlled trial has two arms: vilobelimab (2400mg every
other week) plus a low dose of corticosteroids and placebo plus the
same low dose of corticosteroids. The primary endpoint of the study
is complete closure of the target ulcer at any time up to 26 weeks
after initiation of treatment.
The study has an adaptive trial design with an
interim analysis blinded for the sponsor and investigators planned
upon enrollment of approximately 30 patients (15 per arm).
Depending on the results of the interim analysis, the trial sample
size will be adapted, or the trial will be stopped due to futility.
The enrollment period is projected to be at least two years,
depending on the total trial size after sample size adaptation.
Marketing Authorization Application
(MAA) for Vilobelimab for Treatment of Critically Ill COVID-19
Patients under Review by European Medicines Agency
(EMA)This summer, the Company submitted an MAA for the
treatment of adult patients with SARS-CoV-2 induced septic acute
respiratory distress syndrome (ARDS) receiving invasive mechanical
ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) to
the EMA. The EMA has validated the MAA, which means that the
application is now under regulatory review by the European
Committee for Medicinal Products for Human Use (CHMP) under the
centralized procedure, which applies to all 27 member states of the
European Union.
Commercial Launch of Gohibic
(vilobelimab) for the Treatment of Critically Ill COVID-19 Patients
following Emergency Use Authorization (EUA) in the United
States: In April 2023, the U.S. Food and Drug
Administration (FDA) issued an EUA for Gohibic (vilobelimab) for
the treatment of COVID-19 in hospitalized adults when initiated
within 48 hours of receiving IMV or ECMO. Gohibic (vilobelimab) has
been commercially available to hospitals across the United States
since late Q2 and initial sales were made in Q3.
InflaRx is currently developing its commercial
strategic plan and seeking to increase awareness of Gohibic
(vilobelimab). In parallel, the Company is also exploring paths to
gain full market approval via a biologics license application (BLA)
in the United States. In October 2023, InflaRx held an encouraging
Type C meeting with the FDA related to additional steps towards a
BLA. The FDA indicated that FDA is committed to working with
InflaRx to address challenges and expedite development of
vilobelimab as a treatment for ARDS. In order to obtain a BLA for
ARDS, the Company would need to conduct an additional
well-controlled and adequately powered study in a broader ARDS
setting. InflaRx is exploring different funding options, including
government grants as well as collaborations with third parties.
InflaRx Stops Development of Vilobelimab
in Cutaneous Squamous Cell Carcinoma (cSCC) to Prioritize Other
Programs InflaRx is conducting an open-label,
multicenter Phase II study, evaluating vilobelimab in two study
arms - as a monotherapy (Arm A) and in combination with
pembrolizumab (Arm B) - in patients with programmed cell death
protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1)
inhibitor in resistant/refractory, locally advanced or metastatic
cSCC. The main objectives of this trial are to assess the safety
and antitumor activity of vilobelimab in the monotherapy arm and to
assess the maximum tolerated or recommended dose of vilobelimab and
the safety and antitumor activity of this drug pair in the
combination arm.
An interim analysis of ten evaluable patients in
the monotherapy Arm A showed first evaluable signals of efficacy.
In Arm B, 15 patients were enrolled (3+6+6 in three dosing
cohorts). Before proceeding with the second stage of the study in
Arm B, the interim efficacy data were assessed and showed two
partial responses - one patient in the second cohort and one
patient in the third cohort. Both patients are still on
treatment.
While these results are encouraging, the recent
emergence of new alternative treatments for cSCC and the
recommendation by the Company’s U.S. and international experts to
study additional patients with a higher dose of vilobelimab as
monotherapy would require substantial resources and significantly
extend the timelines of the ongoing clinical program. InflaRx has
therefore decided to stop development in cSCC for the time being
and reallocate resources towards the development of the promising
orally available C5aR inhibitor, INF904.
Patients who are currently still in treatment
will be treated for up to 24 months according to the protocol;
however, no new patients will be enrolled in the study and clinical
sites in which no patients are currently being treated will be
closed down. The decision to wind down this clinical study does not
preclude InflaRx from developing vilobelimab or INF904 in cSCC or
similar oncology indications in the future.
Financing Activities In
October 2021, InflaRx announced the receipt of a grant of up to
€43.7 million from the German Ministry of Education and Research
and the German Ministry of Health to support the development of
vilobelimab for the treatment of severe COVID-19 patients. Due to
subsequent changes in InflaRx’s research and development plan and
fewer costs projected within the timeframe of the grant, the
Company was notified that the amount available would be €41.4
million. The grant was structured as a reimbursement of 80% of
certain pre-specified expenses related to the clinical development
and manufacturing of vilobelimab. The grant period ended on June
30, 2023. During the duration of the grant period and up to this
date, InflaRx has received a total amount of €32.7 million. An
amount of €1.2 million remains outstanding. Such amount is, and
will continue to be, held back by the federal German government
until all conditions of the grant have been fulfilled, including
the government review of the final written report.
Dr. Thomas Taapken, Chief Financial Officer of
InflaRx, said: “This quarter was the first time that InflaRx has
recorded sales revenues, an achievement that very few biotech
companies reach. We are further expanding our commercial activities
over the coming months as cases of severe COVID-19 are anticipated
to increase over the winter months. Our company is funded to
support operations well into 2026, which is important in the
continued challenging financial market environment.”
Financial Highlights – Q3
2023
Revenue In Q3 2023, the
Company realized revenues from product sales for the first time
since its inception. Revenues reported are actual sales to end
customers (hospitals). Sales to distributors, of which €2.9 million
were incurred in Q3, do not constitute revenue for the Company
under IFRS 15 but rather were recorded as other financial liability
as of September 30, 2023. Revenues for the nine months ended
September 30, 2023, amounted to 60 thousand EUR.
Cost of Sales Cost of
sales recognized during the nine months ended September 30, 2023,
are related to Gohibic (vilobelimab) revenues in the United States.
Costs of sales for products sold in this period do not include
costs of materials, as the associated costs of these materials were
incurred in prior periods, before granting of an EUA for Gohibic
(vilobelimab). These materials were recorded as research and
development expenses in the period they were incurred.
Cost of sales during the first nine months of
2023 mainly consisted of write-downs of inventories that will
expire prior to their expected sale. Early product batches,
capitalized in inventory, were produced with material which had
been manufactured in previous years. The inventory write-down for
the nine months ended September 30, 2023, amounted to €0.3 million,
mainly attributable to shelf-life expiration within the next nine
months.
Sales and Marketing
Expenses In the nine months ended September 30, 2023,
InflaRx incurred €1.8 million of sales and marketing expenses.
These expenses were mainly composed of €0.6 million personnel costs
and €1.1 million external services for distribution.
Research and Development
Expenses Research and development expenses incurred
for the nine months ended September 30, 2023, increased by €3.7
million to € 33.0 million compared to the nine months ended
September 30, 2022, and were predominantly attributable to the
establishment of a commercial-scale manufacturing process for
vilobelimab and regulatory expenses in conjunction with the EUA
filing and other regulatory activities, as well as for the
manufacturing of clinical trial-related material.
General and Administrative
Expenses General and administrative expenses
decreased by €1.8 million to €10.0 million for the nine months
ended September 30, 2023, from €11.8 million for the nine months
ended September 30, 2022. This decrease was primarily attributable
to a decrease in expenses associated with equity-settled
share-based compensation recognized in personnel expenses.
Other Income Other income
decreased by €3.0 million to €13.4 million for the nine months
ended September 30, 2023, from €16.5 million for the nine months
ended September 30, 2022 and was primarily attributable to income
recognized from the grant payments received from the German federal
government for the development of Gohibic (vilobelimab) in severe
COVID-19, including InflaRx’s expenses related to clinical
development and manufacturing process development. The decrease in
income from government grants was primarily due to the completion
of activities under the grant. The grant period ended on June 30,
2023.
Net Financial Result Net
financial result increased by €1.8 million to €4.9 million for the
nine months ended September 30, 2023, from €3.1 million for the
nine months ended September 30, 2022. This increase was mainly
attributable to higher interest income which increased by €2.4
million, partly offset by the decrease in foreign exchange result
of €1.2 million.
Net Loss Net loss for the
first nine months of 2023 amounted to €26.7 million, compared to
€21.5 million in the first nine months of 2022.
Net Cash Used in Operating
Activities Net cash used in operating activities for
the first nine months of 2023 decreased to €26.9 million from €28.5
million for the comparable period in 2022.
Liquidity and Capital
Resources As of September 30, 2023, the Company’s
total available funds were approximately €113 million, composed of
€21.7 million in cash and cash equivalents and €91.4 million in
marketable securities. These funds are expected to finance
operations at least into 2026.
Additional Financial
Information Additional information regarding these
results and other relevant information is included in the notes to
the unaudited interim condensed consolidated financial statements
as of September 30, 2023, and the three and nine months ended
September 30, 2023, and 2022, as well as the consolidated financial
statements as of and for the year ended December 31, 2022, in “ITEM
18. Financial Statements,” in InflaRx’s Annual Report on Form 20-F
for the year ended December 31, 2022, as filed with the U.S.
Securities and Exchange Commission (SEC).
InflaRx N.V. and
subsidiaries
Unaudited Condensed Consolidated Statements
of Operations and Comprehensive Loss for the three and nine months
ended September 30, 2023 and 2022
|
For the three monthsended September
30, |
|
For the nine monthsended September
30 |
|
|
2023(unaudited) |
|
2022(unaudited) |
|
2023(unaudited) |
|
2022(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
(in €, except for share data) |
|
|
|
Revenues |
60,803 |
|
— |
|
60,803 |
|
— |
|
Cost of Sales |
(255,116) |
|
— |
|
(255,116) |
|
— |
|
Gross profit |
(194,313) |
|
— |
|
(194,313) |
|
— |
|
Sales and marketing expenses |
(1,562,473) |
|
— |
|
(1,838,524) |
|
— |
|
Research and development expenses |
(7,305,541) |
|
(7,537,350) |
|
(32,957,044) |
|
(29,190,231) |
|
General and administrative expenses |
(2,897,732) |
|
(3,087,285) |
|
(10,047,091) |
|
(11,821,694) |
|
Other income |
808,866 |
|
2,030,406 |
|
13,437,963 |
|
16,473,540 |
|
Other expenses |
339 |
|
— |
|
(2,851) |
|
(844) |
|
Operating Result |
(11,150,854) |
|
(8,594,230) |
|
(31,601,861) |
|
(24,539,229) |
|
Finance income |
1,189,826 |
|
199,758 |
|
2,732,873 |
|
310,121 |
|
Finance expenses |
(4,897) |
|
(6,845) |
|
(15,476) |
|
(39,376) |
|
Foreign exchange result |
2,292,938 |
|
882,370 |
|
1,923,274 |
|
3,173,883 |
|
Other financial result |
221,577 |
|
(402,724) |
|
223,818 |
|
(363,724) |
|
Income Taxes |
— |
|
— |
|
— |
|
— |
|
Income (Loss) for the Period |
(7,451,410) |
|
(7,921,671) |
|
(26,737,373) |
|
(21,458,325) |
|
|
|
|
|
|
Other comprehensive income (loss) that may be reclassified to
profit or loss in subsequent periods: |
|
|
|
|
Exchange differences on translation of foreign currency |
73,574 |
|
4,317,134 |
|
56,459 |
|
10,035,949 |
|
Total Comprehensive Income (Loss) |
(7,377,836) |
|
(3,604,538) |
|
(26,680,914) |
|
(11,422,376) |
|
|
|
|
|
|
|
|
|
|
|
Share Information (based on Income (Loss) for the
Period) |
|
|
|
|
Weighted average number of shares outstanding |
58,883,272 |
|
44,203,763 |
|
53,598,594 |
|
44,203,763 |
|
Income (Loss) per share (basic/diluted) |
(0.13) |
|
(0.18) |
|
(0.50) |
|
(0.49) |
|
InflaRx N.V. and
subsidiaries
Unaudited Condensed Consolidated Statements
of Financial Position as of September 30, 2023 and December 31,
2022
|
September 30,
2023(unaudited) |
|
December 31, 2022 |
|
|
|
|
(in €) |
ASSETS |
|
|
|
|
Non-current assets |
|
|
|
|
Property and equipment |
298,344 |
|
328,920 |
|
Right-of-use assets |
1,076,402 |
|
1,311,809 |
|
Intangible assets |
66,734 |
|
138,905 |
|
Other assets |
270,526 |
|
308,066 |
|
Financial assets |
237,564 |
|
2,900,902 |
|
Total non-current assets |
1,949,570 |
|
4,988,602 |
|
Current assets |
|
|
|
|
Inventories |
1,639,490 |
|
— |
|
Current other assets |
7,779,994 |
|
14,170,510 |
|
Current tax assets |
3,398,481 |
|
1,432,087 |
|
Financial assets from government grants |
1,164,217 |
|
732,971 |
|
Other financial assets |
91,857,945 |
|
64,810,135 |
|
Cash and cash equivalents |
21,695,607 |
|
16,265,355 |
|
Total current assets |
127,535,734 |
|
97,411,058 |
|
TOTAL ASSETS |
129,485,304 |
|
102,399,660 |
|
|
|
|
|
|
EQUITY AND LIABILITIES |
|
|
|
|
Equity |
|
|
|
|
Issued capital |
7,065,993 |
|
5,364,452 |
|
Share premium |
334,211,338 |
|
282,552,633 |
|
Other capital reserves |
39,597,055 |
|
36,635,564 |
|
Accumulated deficit |
(270,197,663) |
|
(243,460,290) |
|
Other components of equity |
7,313,540 |
|
7,257,081 |
|
Total equity |
117,990,262 |
|
88,349,440 |
|
Non-current liabilities |
|
|
|
|
Lease liabilities |
771,814 |
|
987,307 |
|
Other liabilities |
36,877 |
|
36,877 |
|
Total non-current liabilities |
808,691 |
|
1,024,184 |
|
Current liabilities |
|
|
|
|
Trade and other payables |
5,999,200 |
|
4,987,538 |
|
Liabilities from government grants |
— |
|
6,209,266 |
|
Lease liabilities |
354,151 |
|
369,376 |
|
Employee benefits |
1,285,355 |
|
1,312,248 |
|
Other liabilities |
3,047,646 |
|
147,608 |
|
Total current liabilities |
10,686,351 |
|
13,026,036 |
|
Total Liabilities |
11,495,042 |
|
14,050,220 |
|
TOTAL EQUITY AND LIABILITIES |
129,485,304 |
|
102,399,660 |
|
|
|
|
|
|
InflaRx N.V. and
subsidiaries
Unaudited Condensed Consolidated Statements
of Changes in Shareholders’ Equity for the nine months ended
September 30, 2023 and 2022
(in €) |
Issued capital |
|
Sharepremium |
|
Other capital reserves |
|
Accumulated deficit |
|
Other components of equity |
|
Total equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2023 |
5,364,452 |
|
282,552,633 |
|
36,635,564 |
|
(243,460,290) |
|
7,257,081 |
|
88,349,440 |
|
Loss for the period |
— |
|
— |
|
— |
|
(26,737,373) |
|
— |
|
(26,737,373) |
|
Exchange differences on translation of foreign currency |
— |
|
— |
|
— |
|
— |
|
56,459 |
|
56,459 |
|
Total comprehensive loss |
— |
|
— |
|
— |
|
(26,737,373) |
|
56,459 |
|
(26,680,914) |
|
Issuance of common shares |
1,687,110 |
|
54,796,819 |
|
— |
|
— |
|
— |
|
56,483,929 |
|
Transaction costs |
— |
|
(3,360,626) |
|
— |
|
— |
|
— |
|
(3,360,626) |
|
Equity-settled share-based payments |
— |
|
— |
|
2,961,491 |
|
— |
|
— |
|
2,961,491 |
|
Share options exercised |
14,431 |
|
222,512 |
|
— |
|
— |
|
— |
|
236,943 |
|
Balance as of September 30, 2023 |
7,065,993 |
|
334,211,338 |
|
39,597,055 |
|
(270,197,663) |
|
7,313,540 |
|
117,990,262 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2022 |
5,304,452 |
|
280,310,744 |
|
30,591,209 |
|
(213,975,679) |
|
3,050,271 |
|
105,280,996 |
|
Loss for the period |
— |
|
— |
|
— |
|
(21,458,325) |
|
— |
|
(21,458,325) |
|
Exchange differences on translation of foreign currency |
— |
|
— |
|
— |
|
— |
|
10,035,949 |
|
10,035,949 |
|
Total comprehensive loss |
— |
|
— |
|
— |
|
(21,458,325) |
|
10,035,949 |
|
(11,422,376) |
|
Equity-settled share-based payments |
— |
|
— |
|
5,581,021 |
|
— |
|
— |
|
5,581,021 |
|
Balance as of September 30, 2022 |
5,304,452 |
|
280,310,744 |
|
36,172,229 |
|
(235,434,004) |
|
13,086,220 |
|
99,439,640 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
InflaRx N.V. and
subsidiaries
Unaudited Condensed Consolidated
Statements of Cash Flows for the nine months ended September 30,
2023 and 2022
|
For the nine months ended September 30, |
|
|
2023(unaudited) |
|
2022(unaudited) |
|
|
|
|
(in €) |
Operating activities |
|
|
Loss for the period |
(26,737,373) |
|
(21,458,325) |
|
Adjustments for: |
|
|
Depreciation & amortization of property and equipment,
right-of-use assets and intangible assets |
432,248 |
|
448,323 |
|
Net finance income |
(4,864,488) |
|
(3,080,904) |
|
Share-based payment expense |
2,961,491 |
|
5,581,021 |
|
Net foreign exchange differences |
(82,574) |
|
189,088 |
|
Changes in: |
|
|
|
|
Financial assets from government grants |
(431,246) |
|
(5,954,754) |
|
Other assets |
4,468,239 |
|
3,087,177 |
|
Employee benefits |
(26,893) |
|
(221,982) |
|
Other liabilities |
2,893,461 |
|
5,061 |
|
Liabilities from government grants received |
(6,209,266) |
|
(6,849,415) |
|
Trade and other payables |
1,011,662 |
|
(1,135,817) |
|
Inventories |
(1,639,490) |
|
— |
|
Interest received |
1,302,391 |
|
903,647 |
|
Interest paid |
(15,773) |
|
(38,978) |
|
Net cash used in operating activities |
(26,937,611) |
|
(28,525,857) |
|
Investing activities |
|
|
|
|
Purchase of intangible assets, property and equipment |
(45,942) |
|
(17,908) |
|
Purchase of current financial assets |
(91,590,134) |
|
(47,031,216) |
|
Proceeds from the maturity of financial assets |
71,113,455 |
|
64,600,049 |
|
Net cash from/(used in) investing activities |
(20,522,621) |
|
17,550,925 |
|
Financing activities |
|
|
|
|
Proceeds from issuance of common shares |
56,483,929 |
|
— |
|
Transaction costs from issuance of common shares |
(3,360,626) |
|
— |
|
Proceeds from exercise of share options |
236,943 |
|
— |
|
Repayment of lease liabilities |
(279,075) |
|
(273,092) |
|
Net cash from/(used in) financing activities |
53,081,170 |
|
(273,092) |
|
Net increase/(decrease) in cash and cash equivalents |
5,620,938 |
|
(11,248,024) |
|
Effect of exchange rate changes on cash and cash equivalents |
(190,686) |
|
2,976,033 |
|
Cash and cash equivalents at beginning of period |
16,265,355 |
|
26,249,995 |
|
Cash and cash equivalents at end of period |
21,695,607 |
|
17,978,003 |
|
|
|
|
|
|
About InflaRx InflaRx GmbH
(Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned
subsidiaries of InflaRx N.V. (together, InflaRx).
InflaRx (Nasdaq: IFRX) is a biotechnology
company pioneering anti-inflammatory therapeutics by applying its
proprietary anti-C5a and anti-C5aR technologies to discover,
develop and commercialize first-in-class, potent and specific
inhibitors of the complement activation factor C5a and its receptor
C5aR. C5a is a powerful inflammatory mediator involved in the
progression of a wide variety of inflammatory diseases. InflaRx’s
lead product candidate, vilobelimab, is a novel, intravenously
delivered, first-in-class, anti-C5a monoclonal antibody that
selectively binds to free C5a and has demonstrated
disease-modifying clinical activity and tolerability in multiple
clinical studies in different indications. InflaRx was founded in
2007, and the group has offices and subsidiaries in Jena and
Munich, Germany, as well as Ann Arbor, MI, USA. For further
information, please visit www.inflarx.com.
The COVID-19 related work described herein is
partly funded by the German Federal Government through grant number
16LW0113 (VILO-COVID). All responsibility for the content of this
work lies with InflaRx.
Contacts:
InflaRx N.V.Email: IR@inflarx.de
MC Services AGKatja Arnold, Laurie Doyle, Dr.
Regina LutzEmail: inflarx@mc-services.eu Europe: +49 89-210
2280U.S.: +1-339-832-0752
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “estimate,” “believe,”
“predict,” “potential” or “continue,” among others. Forward-looking
statements appear in a number of places throughout this release and
may include statements regarding our intentions, beliefs,
projections, outlook, analyses and current expectations concerning,
among other things, the receptiveness of Gohibic (vilobelimab) as a
treatment for COVID-19 by COVID-19 patients and U.S. hospitals and
related treatment recommendations by medical/healthcare institutes
and other third-party organizations, our ability to successfully
commercialize and the receptiveness of Gohibic (vilobelimab) as a
treatment for COVID-19 by COVID-19 patients and U.S. hospitals or
our other product candidates; our expectations regarding the size
of the patient populations for, market opportunity for, coverage
and reimbursement for, estimated returns and return accruals for,
and clinical utility of Gohibic (vilobelimab) in its approved or
authorized indication or for vilobelimab and any other product
candidates, under an EUA and in the future if approved for
commercial use in the United States or elsewhere; the success of
our future clinical trials for vilobelimab and any other product
candidates and whether such clinical results will reflect results
seen in previously conducted pre-clinical studies and clinical
trials; the timing, progress and results of pre-clinical studies
and clinical trials of our product candidates, including the MAD
part of the Phase 1 trial with C5aR inhibitor INF904, and
statements regarding the timing of initiation and completion of
studies or trials and related preparatory work, the period during
which the results of the trials will become available, the costs of
such trials and our research and development programs generally;
our interactions with regulators regarding the results of clinical
trials and potential regulatory approval pathways, including
related to our MAA submission for vilobelimab and our BLA
submission for Gohibic (vilobelimab), and our ability to obtain and
maintain full regulatory approval of vilobelimab or Gohibic
(vilobelimab) for any indication; whether the FDA, the EMA or any
comparable foreign regulatory authority will accept or agree with
the number, design, size, conduct or implementation of our clinical
trials, including any proposed primary or secondary endpoints for
such trials; our expectations regarding the scope of any approved
indication for vilobelimab; our ability to leverage our proprietary
anti-C5a and C5aR technologies to discover and develop therapies to
treat complement-mediated autoimmune and inflammatory diseases; our
ability to protect, maintain and enforce our intellectual property
protection for vilobelimab and any other product candidates, and
the scope of such protection; our manufacturing capabilities and
strategy, including the scalability and cost of our manufacturing
methods and processes and the optimization of our manufacturing
methods and processes, and our ability to continue to rely on our
existing third-party manufacturers and our ability to engage
additional third-party manufacturers for our planned future
clinical trials and for commercial supply of vilobelimab and for
the finished product Gohibic (vilobelimab); our estimates of our
expenses, ongoing losses, future revenue, capital requirements and
our needs for or ability to obtain additional financing; our
ability to defend against liability claims resulting from the
testing of our product candidates in the clinic or, if approved,
any commercial sales; if any of our product candidates obtain
regulatory approval, our ability to comply with and satisfy ongoing
obligations and continued regulatory overview; our ability to
comply with enacted and future legislation in seeking marketing
approval and commercialization; our future growth and ability to
compete, which depends on our retaining key personnel and
recruiting additional qualified personnel; and our competitive
position and the development of and projections relating to our
competitors in the development of C5a and C5aR inhibitors or our
industry; and the risks, uncertainties and other factors described
under the heading “Risk Factors” in our periodic filings with the
SEC. These statements speak only as of the date of this press
release and involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Given these risks, uncertainties
and other factors, you should not place undue reliance on these
forward-looking statements, and we assume no obligation to update
these forward-looking statements, even if new information becomes
available in the future, except as required by law.
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024